Brief: Geneuro/Fondamental Foundation: Early Results For Treatment Of Patients With Post-Covid Neuropsychiatric Syndromes

Geneuro SA

13/04/2022 06:44

April 13 (Reuters) - Geneuro SA  GNRO.PA :
    * GENEURO AND FONDAMENTAL FOUNDATION ANNOUNCE FIRST RESULTS
OF
COLLABORATION FOR DEVELOPMENT OF DIAGNOSTIC AND THERAPEUTIC
OPTIONS FOR PATIENTS WITH POST-COVID NEUROPSYCHIATRIC SYNDROMES
    * GENEURO IS PREPARING TO LAUNCH A PHASE 2 CLINICAL TRIAL IN
200
PATIENTS WITH POST-COVID SYNDROMES AND POSITIVE FOR W-ENV
    * STUDY SHOWS A STRONG CORRELATION BETWEEN SARS-COV-2
INFECTION,
W-ENV PROTEIN AND MARKERS OF INNATE IMMUNITY, IN PATIENTS WITH
PSYCHIATRIC DISORDERS
    * RESULTS CONFIRM INTEREST OF TREATING POST-COVID
NEUROPSYCHIATRIC
SYNDROMES BY NEUTRALIZING W-ENV PROTEIN WITH TEMELIMAB ANTIBODY
    * THE OBJECTIVE OF THIS ANALYSIS WAS TO MEASURE THE
CORONAVIRUS
INFECTION RATE IN A POPULATION WITH NO REPORTED COVID DISEASE
AND TO SEARCH FOR LINKS BETWEEN SARS-COV-2 INFECTION AND THE
ENDOGENOUS RETROVIRAL PROTEIN W-ENV
    * GENEURO IS PREPARING TO LAUNCH A CLINICAL TRIAL IN 200
W-ENV
POSITIVE PATIENTS WITH POST-COVID NEUROPSYCHIATRIC SYNDROMES
    * FUTURE CLINICAL TRIAL IN 200 W-ENV POSITIVE PATIENTS WITH
POST-COVID NEUROPSYCHIATRIC SYNDROMES IS CO-FINANCED BY THE
SWISS FEDERAL OFFICE OF PUBLIC HEALTH

Source text for Eikon:  ID:nBw1PTZ88a 
Further company coverage:  GNRO.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))